STOCK TITAN
  1. Home
  2. Sec-filings
  3. GOVX
  4. [PRE 14A] GeoVax Labs, Inc. Preliminary Proxy Statement

[PRE 14A] GeoVax Labs, Inc. Preliminary Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
PRE 14A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock GOVX logo
Geovax Labs Inc

NASDAQ:GOVX

GOVX Rankings

#6004 Ranked by Market Cap
N/A Ranked by Dividends

GOVX Latest News

Dec 9, 2024
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
Nov 26, 2024
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
Nov 19, 2024
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
Nov 12, 2024
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 5, 2024
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GOVX Latest SEC Filings

Sep 30, 2025
[8-K] GeoVax Labs, Inc. Reports Material Event
Sep 30, 2025
[424B5] GeoVax Labs, Inc. Prospectus Supplement (Debt Securities)
Sep 29, 2025
[25-NSE] GeoVax Labs, Inc. SEC Filing
Sep 19, 2025
[424B5] GeoVax Labs, Inc. Prospectus Supplement (Debt Securities)

GOVX Stock Data

16.51M
28.15M
6.07%
12.73%
16.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SMYRNA